Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 6 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.

Integrating genetic testing into routine oncology care in the UK

Dr Joslyn Ngu
04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

Despite the many advantages of genetic testing, patients with ovarian cancer are historically under-referred, said Dr Angela George, consultant oncogenetics and clinical lead of the Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, UK. The reasons for this include the failures to take family history; to recognize family history; and to refer.

The integration of genetic testing into routine oncology care requires the education of clinicians, oncologists and specialized nurses so they are well-equipped to take consent from patients for genetic testing, said George. Once patients who fit the pre-agreed criteria for testing gives their consent, healthcare professionals in the clinic can obtain the necessary blood samples and send them together with the forms to a genetics centre. This will reduce the need for patients to make additional appointments with the genetics department, which means no extra appointments and no waiting for referral, she said.

In the UK, a training programme for healthcare professionals to perform BRCA gene testing for breast and ovarian cancer is available on Youtube and a certificate of completion is provided, said George.

Ovarian cancer is a good example to showcase the benefits of mainstreaming genetic testing. An estimated 15 percent of ovarian cancer have a BRCA 1 or BRCA 2 mutation. [Sci Rep 2016;6:29506. Doi: 10.1038/srep29506]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 6 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.